NovoCure Limited (NVCR)
Nasdaq: NVCR · Surgical & Medical Instruments & Apparatus · filing with the SEC since 2015
Who owns NovoCure Limited
As filed with the SECHolders of 5% or more
3
Soleus Capital Master Fund, L.P. holds 9.1% of Ordinary Shares, no par value per share, as its SCHEDULE 13G/A filed May 8, 2026 says.
Directors and officers
18
report now, of 35 people on the record since 2015. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Soleus Capital Master Fund, L.P.
SCHEDULE 13G/A · filed May 8, 2026 · Ordinary Shares, no par value per share · 7.6% in Feb 12, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 23, 2025 · Common Stock
Vanguard Portfolio Management
SCHEDULE 13G · filed Apr 28, 2026 · Common Stock
Capital World Investors
SCHEDULE 13G/A · filed Nov 13, 2025 · Common Stock · reported falling below 5%, from 5.7% in Aug 13, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
Capital International Investors
SCHEDULE 13G/A · filed Jul 7, 2025 · Common Stock · reported falling below 5%
What NVCR reports owning in othersstakes of 5% or more, and other ties
20 subsidiaries in 18 countries, from the list filed with the 10-K filed Feb 26, 2026.
Insider tradesForm 4
28sales
0purchases
0sales on a scheduled plan
14people selling
$3.4Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window14 of 46 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Leonard Frank X | Chief Executive Officer | 4 | $900,000 | 0 | 0 | $0 |
| Doyle William F | Executive Chairman | 2 | $900,000 | 0 | 0 | $0 |
| Paravasthu Mukund | Chief Operating Officer | 5 | $700,000 | 0 | 0 | $0 |
| Brackmann Christoph | Chief Financial Officer | 2 | $200,000 | 0 | 0 | $0 |
| Weinberg Uri | Chf Medical and Innovation Ofr | 3 | $200,000 | 0 | 0 | $0 |
| Puri Michal Nath | Chief Human Resources Officer | 3 | $0 | 0 | 0 | $0 |
| Leupin Nicolas | Former Chief Medical Officer | 2 | $0 | 0 | 0 | $0 |
| Hilleman Jeryl L | director | 1 | $0 | 0 | 0 | $0 |
| Hung David | director | 1 | $0 | 0 | 0 | $0 |
| Leung Gabriel | director | 1 | $0 | 0 | 0 | $0 |
| Ocean Allyson J | director | 1 | $0 | 0 | 0 | $0 |
| Scannell Timothy J | director | 1 | $0 | 0 | 0 | $0 |
| Stafford Kristin | director | 1 | $0 | 0 | 0 | $0 |
| Vernon W Anthony | director | 1 | $0 | 0 | 0 | $0 |